CBD Life Sciences Inc.
CBDL
$0.0004
$0.000.00%
| Weiss Ratings | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -55.61 | |||
| Price History | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | -50.00% | |||
| Year to Date Total Return | -20.00% | |||
| 1-Year Total Return | -97.33% | |||
| 2-Year Total Return | -97.33% | |||
| 3-Year Total Return | -99.33% | |||
| 5-Year Total Return | -99.78% | |||
| 52-Week High % Change | -98.67% | |||
| 52-Week Low % Change | 33.33% | |||
| Price | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.03 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Mar 14, 2024 | |||
| 52-Week High Price (Date) | Mar 14, 2024 | |||
| Valuation | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.24M | |||
| Enterprise Value | 1.30M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -76.47% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.33 | |||
| Price/Book (Q) | 0.21 | |||
| Enterprise Value/Revenue (TTM) | 30.42 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -38.49 | |||
| Enterprise Value/EBIT | -24.90 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 135.69M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 480 410 6780 | |||
| Address | 10855 N 116th Street Scottsdale, AZ 85259 | |||
| Website | lbcbioscienceinc.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -- | |||
| Net Income (TTM) | -- | |||
| Net Income Avl. to Common (TTM) | -- | |||
| Total Revenue Growth (Q YOY) | 36.19% | |||
| Earnings Growth (Q YOY) | -122.98% | |||
| EPS Diluted (TTM) | -- | |||
| EPS Diluted Growth (Q YOY) | -100.00% | |||
| Balance Sheet | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 100.00 | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 185.30K | |||
| Total Preferred Equity (Q) | 0.07 | |||
| Total Equity (Q) | 342.20K | |||
| Current Ratio (Q) | 4.164 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 386.70K | |||
| Total Current Liabilities (Q) | 44.50K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 44.50K | |||
| Total Common Equity (Q) | 276.10K | |||
| Cash Flow | CBDL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -- | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | -- | |||
